Accueil > Théa Announces FDA Approval of IYUZEH™

Théa Announces FDA Approval of IYUZEH™

Théa Announces FDA Approval of IYUZEH™ for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-angle Glaucoma or Ocular Hypertension. IYUZEH™ (latanoprost ophthalmic solution) 0.005% is the first and only clinically proven form of latanoprost available in the United States that is preservative-free and now officially approved by the FDA.
“The approval of IYUZEH™ is a significant milestone for Théa Group, as this is our first FDA approval for a prescription ophthalmic medicine, for our U.S. subsidiary,” said Jean-Frédéric Chibret, President of the Théa Group. “We are extremely proud to bring our unique preservative-free latanoprost eye drop, IYUZEH™ to the U.S.”
To read the press release and for more information on IYUZEH™, click here